GH Research (NASDAQ:GHRS) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock. HC Wainwright also issued estimates for GH Research’s FY2024 earnings at ($0.76) EPS, Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($1.18) EPS.

A number of other brokerages have also recently issued reports on GHRS. Canaccord Genuity Group decreased their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

GHRS opened at $9.27 on Wednesday. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The firm has a market cap of $482.32 million, a P/E ratio of -11.73 and a beta of 0.74. The business’s fifty day moving average is $7.91 and its 200-day moving average is $10.30.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, research analysts predict that GH Research will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its stake in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,251,714 shares of the company’s stock after buying an additional 664,381 shares during the quarter. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).